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Abstract  
Objectives: To critically review conceptual frameworks for available patient reported 
outcome (PRO) questionnaires in men having radical prostatectomy; psychometrically 
evaluate each questionnaire; identify whether each is appropriate for use at the level of the 
individual patient.  
 
Materials and Methods: We searched PubMed, the Reports and Publications database of 
the University of Oxford Patient Reported Outcomes Measurement Group and the website 
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of the International Consortium for Health Outcomes Measurement (ICHOM) for 
psychometric reviews of prostate cancer specific PRO questionnaires.  From these we 
identified relevant questionnaires and critically appraised the conceptual content, guided by 
the Wilson and Cleary framework and psychometric properties, using well established 
criteria. 
 
Results: Searches found four reviews and one recommendation paper.  We identified seven 
prostate cancer specific PROs (EPIC-26, EPIC-50, UCLA-PCI, FACT-P, QLQ-PR25, and PC-QoL 
and STAR).  Six out of seven measures purported to measure health related quality of life, 
but items focused strongly on urinary and sexual symptoms/functioning.  The remaining 
questionnaire (STAR) claimed to assess functional recovery after radical prostatectomy.  The 
psychometric evidence for these questionnaires was incomplete and variable in quality; 
none had evidence that they were appropriate for use with individual patients. 
 
Conclusion: Several questionnaires provide the basis of measures of urinary and/or sexual 
symptoms/functioning.  Further work should explore other aspects of health related quality 
of life that are important for men having radical prostatectomy.  Further psychometric work 
is also needed to determine whether they can be used at the individual level.   
 
INTRODUCTION 
 
Patient reported outcomes (PROs) are increasingly being used.  Patients’ reports of 
symptoms, function and health-related quality of life (HRQL) or overall quality of life (QoL) 
can provide important information about the impact that health problems and related 
treatments have on patients’ lives [1, 2].  These terms are often used interchangeably and 
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for the remainder of this paper we will use the term HRQL.  Typically, PROs are used to 
study outcomes at group level.  However, in some prostate cancer centres, a formal tool for 
the collection of PROs has been implemented in routine clinical practice to monitor 
outcomes in individual patients after radical surgery [3]. 
 
In the UK, around 10% of men newly diagnosed with prostate cancer have a radical 
prostatectomy [4]. In addition to cancer cure, surgeons consider the absence of side effects, 
such as urinary incontinence and erectile dysfunction, as important indicators of the success 
of the surgery.  Men themselves are interested in a wider range of outcomes [5], including 
anxiety and distress, social interactions and intimate relations [6], feelings of masculinity, 
and self-esteem [7].  It is therefore important that both developers and users of PRO 
questionnaires for men diagnosed with prostate cancer are clear about what the 
questionnaire is supposed to measure, whether the questionnaire actually measures these 
concepts, and how well it does so. 
 
Several reviews have evaluated the scientific or psychometric properties of existing PRO 
questionnaires that are being used for patients diagnosed with prostate cancer [8-10].  In 
general, these reviews have used well-established guidelines and criteria based on classical-
test theory to evaluate the robustness of existing instruments [11-13].  The performance of 
these instruments is often expressed in terms of reliability (the extent to which an 
instrument is free from error), validity (the extent to which it measures what it aims to 
measure), and responsiveness (the ability to detect clinically important changes over time).  
However, none of the existing reviews has included a critical review of the conceptual 
content of existing instruments nor evaluated the extent to which these instruments are fit 
to monitor outcomes in individual patients. 
 
To evaluate instruments’ fitness to measure outcomes at the individual level, modern 
psychometric approaches are now often used, such as Rasch measurement theory (RMT) 
and item response theory (IRT) [14-16]. Scores derived from these approaches have a 
number of advantages over methods based on classical-test theory: they are truly “interval 
scores”, meaning that there is an equal distance between each of the values on the scale (as 
opposed to ordinal scores where values are in rank order but the distance between any two 
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values may not be equal), “invariant” (independent of both the distribution of items and the 
distribution of the sample), and potentially appropriate for use in individual patients. 
 
Inconsistency about how HRQL is defined adds to the complexity of evaluating PRO 
questionnaires that claim to measure these constructs.  Although there is no universal 
definition of HRQL, it is generally agreed that it is multi-dimensional and subjective [17-19].  
That is, HRQL focuses on the perceived impact (from the patient’s perspective) of physical, 
mental and social domains of health.  HRQL is therefore not usually concerned with how 
much of a symptom a patient has, but rather to what extent the patient is “bothered by” or 
“concerned about” that symptom.  In addition, Wilson and Cleary [20] have provided a 
conceptual framework that places HRQL in the wider context of health outcomes and 
suggests how HRQL is related to other health outcomes widely used in clinical and health 
services research.  They distinguish five levels of outcome: “biological and physiological 
variables”, “symptom status”, “functional status”, ”general health perceptions”, and 
“overall QoL”. These five outcomes are considered to be separate constructs that are 
causally related (e.g. “symptom status” will affect “functional status” which in turn is likely 
to affect HRQL).  It is important to note that the “overall QoL” construct in the Wilson and 
Cleary framework should reflect individuals’ subjective perception of how happy or satisfied 
they are with their life as a whole.   
 
To address the shortcomings of previous reviews, and to evaluate whether the HRQL 
outcomes that are important to men are being assessed, we carried out a review of the 
existing psychometric reviews of prostate cancer-specific instruments developed to collect 
PROs.  Our aims were to 1) critically review the conceptual content of available PRO 
questionnaires used in men having radical prostatectomy, 2) psychometrically evaluate each 
instrument and 3) determine the extent to which each instrument is appropriate for use in 
individual patients. We used this review-of-reviews to identify the original development 
articles and we applied the Wilson and Cleary framework as the basis for a critical appraisal 
of the instruments’ conceptual content [20].  We also summarised the available 
psychometric evidence for each instrument and assessed the extent to which each 
instrument is appropriate for use in individual patients. 
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METHODS 
 
Search strategy 
We searched the PubMed database from its beginning to June 2015 to identify 
psychometric reviews of prostate cancer-specific PRO questionnaires.  We searched 
PubMed using the following search strategy: (“quality of life” OR “QoL” OR “HRQL” OR 
“symptom” OR “function” OR “disability” OR “patient reported outcome”) AND (“prostate”) 
AND (“instrument” OR “measure ” OR “questionnaire”), limited by “review” and “systematic 
review”. 
 
To identify additional reviews we searched the Reports and Publications database of the 
University of Oxford Patient Reported Outcomes Measurement Group [21].  We also 
searched the website of the International Consortium for Health Outcomes Measurement 
(ICHOM) for reports of recommendations on prostate cancer-specific PROs [21]. 
 
Instrument selection 
From the identified review papers, we compiled a list of instruments recommended by the 
reviewers following psychometric assessment, and located the original development 
articles.  We excluded instruments developed in languages other than English, generic 
cancer-related instruments, instruments that were designed to capture utilities (i.e. 
quantitative measures of individuals’ preferences for specific health states), instruments not 
developed for use in patients with prostate cancer, and instruments specifically designed to 
be used in men who had prostate cancer treatments other than radical prostatectomy.  
Single question assessments were also excluded. 
 
Data extraction and appraisal 
We identified the original development article(s) for each instrument, and extracted data 
for each instrument, using a standard data extraction form derived from Smith et al 2005 
[22].  The criteria used for this appraisal are described in Table 1 and based on well-
established classical psychometric criteria [11, 12, 23].  We chose these guidelines because 
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they were specifically focused on the criteria for the psychometric properties that an 
instrument must have, rather than the quality of the paper reporting the instrument 
development, which the COSMIN guidelines address [24]. To assess content validity we also 
undertook a conceptual review of each of the identified instruments using the five levels of 
outcome included in the Wilson and Cleary framework [20].  We used this framework as a 
guide to compare the items of each instrument with the construct that each instrument 
claimed to measure.  For example, if an instrument claimed to measure HRQL, we expected 
items to reflect the subjectively perceived impact of physical, mental and social domains of 
health rather than the objective level of physical, mental or social health.  That is, an item 
measuring HRQL would ask about the extent to which a man is concerned or bothered by 
his symptoms rather than the extent to which he has symptoms.  Two authors (SCS, EP) 
reviewed each instrument using the standard extraction form.  These two authors 
completed the review independently and then discussed any discrepancies until reaching 
consensus. 
 
 
RESULTS 
 
The literature search generated 450 review papers.  447 articles were identified via 
PubMed, while three articles were identified from the remaining sources.  After removing 
duplicates, a total of 448 abstracts were screened and 33 full-text articles reviewed. Four 
papers presenting the results of psychometric reviews [8-10, 25] were identified and one 
paper describing recommendations by ICHOM [26] (Figure 1).  
 
Based on the recommendations made by these five papers, we identified six prostate 
cancer-specific PRO questionnaires for further review (EPIC-26, EPIC-50, UCLA-PCI, FACT-P, 
QLQ-PR25, and PC-QoL) and located the original development article for each [27-35].  
FACT-P [33] and EORTC QLQ-C30 [36] are generic cancer-related QoL instruments with an 
additional prostate cancer-specific module. The prostate cancer specific module of EORTC 
QLQ-C30 is known as QLQ-PR25 [34].  We evaluated only the prostate cancer specific 
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subscales for these two PRO questionnaires.  An instrument, developed by Memorial Sloan 
Kettering Cancer Center (New York, US), known as STAR [3], to monitor PROs following 
radical prostatectomy in routine clinical practice is also included in this review because it is 
widely used, and was developed specifically for repeat use in men having radical 
prostatectomy.  Therefore, seven instruments are described in Table 2. 
 
 
Conceptual Review 
Our conceptual review addressed the content validity of each instrument in terms of the 
extent to which the items in each instrument reflected the construct that the developers 
claimed the instrument measured.  The developers of six of the seven identified instruments 
themselves used the terms “HRQL” or “overall QL” to describe what  their instruments 
measured (EPIC-26, EPIC-50, UCLA-PCI, EORTC QLQ-PR25, and PC-QoL).1  The remaining 
instrument, (STAR) aimed to measure “functional recovery” after radical prostatectomy.   
  
The results of our conceptual review are shown in Figures 2 to 8. For each instrument, we 
allocated each item (question) to one of Wilson & Cleary’s levels of outcome (i.e. “biological 
and physiological variables”, “symptom status”, “functional status”, “general health 
perceptions”, and “overall QoL”). This allowed us to critique the conceptual content of each 
instrument by determining which level of outcome each item represented. None of the 
seven instruments include items related to the Wilson and Cleary outcome level labelled as 
“biological and physiological variables”. All instruments include items related to “symptom 
status” or “functional status”, particularly sexual and urinary problems and all instruments 
except EPIC-26 include items about bowel problems. In addition, EPIC-50 and EORTC-QLQ 
also include hormonal symptoms and FACT-P includes other symptoms and functional 
problems, such as weight loss, appetite and pain. 
 
STAR is the only instrument that includes an item related to “general health perceptions”, 
asking about the overall feeling related to the current state of health. 
                                                        
1 Please note that these are the terms are used by the developers.  They often did not explicitly define what 
these terms included and do not necessarily reflect the definitions used in the conceptual framework 
proposed by Wilson and Cleary.14 
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All instruments included some items that can be labelled as “QoL”.  Across all instruments 
these are mostly focused on the subjective impact of physical health, with fewer items 
representing the perceived impact of mental health.  EPIC-26, EPIC-50 and PC-QOL include 
the most items that can be labelled as “QoL”.  In general, most of these items reflect the 
subjective impact of physical aspects of health (e.g. the extent to which dripping or leaking 
urine is perceived as a problem or the extent to which changes in body weight are perceived 
as a problem).  PC-QOL also includes items that reflect the impact of mental aspects of 
health (e.g. concern/anxiety about treatment, recurrence, and quality of care).  However, 
items reflecting the subjective impact of social aspects of health were less common.  Only 
PC-QOL includes an item about worry arising from being unable to please a partner sexually, 
an aspect of social health.   
 
In the items that could be labelled as Wilson & Cleary’s term “overall QOL” (though this was 
often described as HRQL by developers of the questionnaires) in the remaining instruments, 
there was a similar predominance of items asking about the subjective impact of physical 
aspects of health.  The HRQL items in QLQ-PR25 include three items about the subjective 
impact of physical health and one about the impact of mental health (feeling less 
masculine).  Similarly, the HRQL items in UCLA-PCI include four items about the subjective 
impact of aspects of physical health (e.g. the extent to which weight gain, weight loss and 
incontinence aids have been a problem) and one item about the impact of mental health 
(feeling less masculine as a result of treatment).  STAR and FACT-P PCS have the narrowest 
HRQL focus. STAR includes two HRQL items, both assessing the subjective impact of aspects 
of physical health (the extent to which urinary and bowel function are a problem).  FACT-P 
PCS includes three HRQL items, of which two assess the subjective impact of physical 
aspects of health (satisfaction with levels of pain and comfort level) and one assesses the 
impact of mental health (ability to feel like a man).   
 
Psychometric appraisal  
The detailed psychometric review of the seven identified instruments, based on their 
development papers is described below, and the results of their psychometric appraisal is 
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shown in Table 3. Overall, the psychometric evidence supporting the instruments was 
patchy and variable in quality. 
 
Classical test theory 
Evidence supporting instrument acceptability was weak for all instruments except EPIC-50, 
with high floor and/or ceiling effects across most instruments. All instruments had evidence 
supporting their reliability, although this evidence was weak for STAR and FACT-P PCS.  
These scales (together with QLQ-PR25) only assessed one type of reliability (internal 
consistency). 
 
For all instruments there was evidence of at least one other form of validity.  This evidence 
was weakest for PCS (FACT-P) which only had weak evidence for known groups differences.  
Validity evidence was moderately strong for the other instruments, across a range of 
different types of validity.    
 
Lastly, evidence regarding the responsiveness of all instruments was very limited which 
makes it impossible to assess the instruments’ ability to detect clinically important 
differences in HRQL in relation to treatment over time. 
 
Modern test theory 
No instrument was developed or subsequently analysed using item response theory or 
Rasch measurement theory. 
 
 
CONCLUSION 
 
We found that the developers of most of the seven identified prostate-cancer specific PROs 
claim that these instruments measure “HRQL” or “overall QoL”, but their items strongly 
focus on urinary, sexual and bowel symptoms and function. All questionnaires include some 
items with a more subjective element to determine the extent to which men are concerned 
or bothered by a particular symptom. However, no instrument includes the full range of 
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items necessary to represent HRQL in terms of the subjective impact of physical, mental and 
social aspects of prostate cancer. These gaps do not only compromise the content validity of 
the six instruments that claim to measure HRQL but they also affect the interpretation of 
the scores and their suitability for use in research and service evaluation.  This means that in 
clinical practice the true impact of prostate cancer treatment is not reflected in the current 
outcomes. The currently available instruments do not measure the range of outcomes that 
are important to men. 
 
Generally, evidence of reliability and validity is incomplete for all instruments. EPIC-50, EPIC-
26 and UCLA-PCI and PC-QOL have most evidence for robust psychometric properties.  Of 
these, EPIC-26 has the advantage that it is well–used and has comparable psychometric 
properties to EPIC-50, but is considerably shorter. However, as none of the instruments has 
evidence of responsiveness it is impossible to draw any conclusion about whether they are 
sensitive to clinically meaningful change.  None of the instruments has been evaluated using 
modern psychometric methods and consequently we have no evidence about how well they 
work at the individual patient level.   
 
Although only PC-QOL had content validity as a measure of HRQL (i.e. it included items 
reflecting the perceived impact of physical, mental and social aspects of health), closer 
inspection of the items across all of the instruments suggests that most reflect the 
recognised side effects of surgery. However, the relatively narrow focus and dearth of items 
reflecting patients’ subjective feelings about the impact of physical, mental and social 
aspects of health means that they may not reflect all the outcomes that are important to 
patients. There is a need for greater qualitative understanding of HRQL for men with 
prostate cancer and to develop questionnaire items that reflect this.  Additionally, further 
psychometric development work is needed, using modern psychometric methods (such as 
IRT or RMT) to determine the extent to which it is appropriate to use these questionnaires 
at the individual level.   
 
Our findings are limited by the fact that we used the instruments that were recommended 
by other reviews. The five reviews overlapped in their recommendations, especially for 
EPIC-50, EPIC-26 and UCLA-PCI.  As these recommendations are often the basis of how 
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researchers and practitioners choose instruments, it is an appropriate shortlist for further 
critique. The authors of each review used slightly different psychometric criteria to reach 
their conclusions, but there was also much similarity in the criteria that were used. 
 
In addition, the review of questionnaire items and their conceptual content involves a 
degree of judgement.  We have made our definitions explicit and based them on the widely 
available and often cited literature in this area.  The categorisation of each item was 
undertaken by two of the authors and later also reviewed by the remaining authors.   
 
The results of our review, and especially the evaluation of conceptual content, suggest that 
the available PROs offer a limited evaluation of the outcomes after radical prostatectomy 
that are relevant to men with prostate cancer. There are gaps in content and also 
inadequate evidence of reliability, validity and responsiveness of the existing instruments.  
 
In conclusion, several instruments provide the basis of measures of urinary symptoms 
and/or sexual function that could potentially be used at the group level. Although the focus 
on symptoms and functional outcomes is of interest to both clinicians and patients, there 
are other aspects of HRQL that need to be explored as important outcomes for men 
receiving surgery for prostate cancer.  As yet, there is no formal evidence to support the 
appropriateness of the questionnaires for use at the individual level. 
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Table 1. Psychometric definitions/tests and appraisal criteria, derived from Smith et al 2005 [22]. 
 
Psychometric 
property 
Definition/test Criteria for acceptability 
1. Item 
analysis/reduction 
Identification of items for possible 
elimination owing to weak psychometric 
performance; assessed on the basis of (1) 
unrotated principal component factor 
analysis to determine whether all items 
are measuring a single factor; and (2) 
item analyses for all items. 
Principal component factor analysis: All 
items should load on the first unrotated 
factor >0.30. 
 
Item analyses (applied to all items):  
Missing data <5%.  
No item redundancy (inter-item 
correlations ≤ 0.75). 
Item–total correlations >0.25 Maximum 
endorsement frequencies ≤80% (i.e. the 
proportion of respondents who endorse 
each response category), including 
floor/ceiling effects <80% (i.e. response 
categories with high endorsement rates at 
the bottom/top ends of the scale, 
respectively).  
Aggregate adjacent endorsement 
frequencies ≥10%. 
2. Acceptability The quality of data; assessed by 
completeness of data and score 
distributions. 
Missing data for summary scores <5%. 
Even distribution of endorsement 
frequencies across response categories. 
Floor/ceiling effects for summary scores 
<10%. 
3. Reliability   
3.1 Internal 
consistency 
The extent to which items comprising a 
scale measure the same construct (e.g. 
homogeneity of the scale); assessed by 
Cronbach’s alpha and item–total 
correlations. 
Cronbach’s alphas for summary scores 
≥0.70. 
Item–total correlations ≥0.20. 
Test–retest reliability correlations for 
summary scores ≥0.70. 
3.2 Test-retest 
reliability 
The stability of a measuring instrument; 
assessed by administering the instrument 
to respondents on two different 
occasions and examining the correlation 
between test and retest scores. 
Test–retest reliability correlations for 
summary scores ≥0.70. 
 
4. Validity   
4.1 Content validity The extent to which the content of a scale 
is representative of the conceptual 
domain it is intended to cover; assessed 
qualitatively during the questionnaire 
development stage through pre-testing 
with patients, expert opinion and 
literature review. 
Qualitative evidence from pre-testing 
with patients, expert opinion and 
literature review that items in the scale 
are representative of the construct being 
measured. 
 
4.2 Criterion-related 
validity 
  
4.2.1 Concurrent 
validity 
Evidence that the scale predicts a gold-
standard criterion that is measured at the 
same time; assessed on the basis of 
correlations between the scale and the 
criterion measure. 
High correlation between the scale and 
the criterion measure. 
 
4.2.2 Predictive 
validity 
Evidence that the scale predicts a gold-
standard criterion that is measured in the 
future; assessed on the basis of 
High correlation between the scale and 
the criterion measure. 
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correlations between the scale and the 
criterion measure. 
4.3 Construct 
validity 
  
4.3.1 Within-scale 
analyses 
Evidence that a single entity (construct) is 
being measured and that items can be 
combined to form a summary score; 
assessed on the basis of evidence of good 
internal consistency and correlations 
between scale scores (which purport to 
measure related aspects of the 
construct). 
Internal consistency (Cronbach’s alpha) ≥ 
0.70. 
Moderate to high correlations between 
scale scores. 
 
4.3.2 Analyses 
against external 
criteria 
  
4.3.2.1 Convergent 
validity 
Evidence that the scale is correlated with 
other instruments measuring the same or 
similar constructs; assessed on the basis 
of correlations between the instrument 
and other similar instruments. 
Correlations are expected to vary 
according to the degree of similarity 
between the constructs that are being 
measured by each instrument. 
Specific hypotheses are formulated and 
predictions tested on the basis of 
correlations. 
4.3.2.2 Discriminant 
validity 
Evidence that the scale is not correlated 
with instruments measuring different 
constructs; assessed on the basis of 
correlations with instruments measuring 
different constructs. 
Low correlations between the instrument 
and instruments measuring different 
constructs. 
 
4.3.2.3 Known 
groups differences 
The ability of a scale to differentiate 
known groups; assessed by comparing 
scores for subgroups who are expected to 
differ on the construct being measured. 
Significant differences between known 
groups or difference of expected 
magnitude. 
 
4.3.2.4 Hypothesis 
testing 
The extent to which the scale confirms 
pre-defined hypotheses regarding 
expected associations or lack of 
association with external factors, such as 
patient characteristics. 
Significant moderate to high correlations, 
or significant associations in the expected 
direction. 
Expected lack of association confirmed. 
5. Responsiveness The ability of a scale to detect clinically 
important change over time; assessed by 
comparing scores before and after an 
intervention of known efficacy (on the 
basis of various methods including t-tests, 
effect sizes, standardised response 
means, or responsiveness statistics). 
Significant differences between known 
groups or difference of expected 
magnitude. 
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Table 2. Description of prostate cancer specific PROs  
 
PRO Author
s 
 
Reviews 
recommen
ding PROs  
Domains (no. 
items) 
Respo
nse 
option
s 
Scoring Target 
population 
Reca
ll 
peri
od 
Administra
tion / 
completio
n time 
STAR 
(Sympto
m 
Tracking 
and 
Reporti
ng) 
Vickers 
et al 
2010 
[3] 
N/A 4 domains (15 
items): Sexual 
function (6 
items), urinary 
function (5 
items), bowel 
function (2 
items) and 
overall quality of 
life (1 item).  
3- to 
6-
point 
Likert 
scales, 
and 
one 
11-
point 
Likert 
scale. 
 
Item 
scores 
summed 
for the 
urinary 
and 
sexual 
function 
scales to 
give 
domain 
scores. 
Domain 
scores 
can also 
be 
transfor
med to a 
0-100 
scale. 
Men 
treated for 
early stage 
prostate 
cancer 
with 
radical 
prostatect
omy. 
Last 
4 
wee
ks. 
Self-
administer
ed. Time 
to 
complete 
unknown. 
EPIC-26 
(Expand
ed 
Prostate 
Index 
Composi
te-26)  
Szyman
ski et al 
2010 
[27] 
Hedgep
eth et 
al 2009 
[28] 
Schmidt et 
al 2014 [9] 
Rnic et al 
2013 [10] 
Martin et 
al 2015 
[26] 
4 domains (26 
items): Urinary 
domain with 
incontinence 
subscale (4), 
irritatation/obstr
uction subscale 
(4), overall 
urinary bother 
item (1); bowel 
domain (6)’ 
sexual domain 
(6); and 
vitality/hormona
l domain (5). 
 
4- and 
5- 
point 
Likert 
scales. 
Item 
scores 
summed 
for each 
scale 
and 
linearly 
transfor
med to 
0-100 
scale. 
Higher 
scores = 
better 
QoL. 
Men 
treated for 
early stage 
prostate 
cancer 
with 
brachyther
apy / 
external 
beam 
radiation / 
radical 
prostatect
omy ± 
adjuvant 
hormonal 
therapy. 
Last 
4 
wee
ks. 
Self-
administer
ed in 10 
minutes. 
EPIC-50  
(Expand
ed 
Prostate 
Index 
Composi
te) 
Wei et 
al 2000 
[29] 
Wei et 
al 2002 
[30] 
Schmidt et 
al 2014 [9] 
Morris et 
al 2009 [8] 
4 domains (50 
items): urinary 
(12) - function 
(5) and bother 
(7); bowel (14) - 
function (7) and 
bother (7); 
sexual (13) - 
function (9) and 
bother (4); 
hormonal (11) - 
function (5) and 
bother (6). 
3- to 
5-
point 
Likert 
scales. 
Item 
scores 
summed 
for each 
domain 
and 
linearly 
transfor
med to 
0-100 
scale. 
Higher 
scores = 
Men 
treated for 
localised 
prostate 
cancer 
with 
brachyther
apy / 
external 
beam 
radiation / 
radical 
prostatect
Last 
4 
wee
ks. 
Self-
administer
ed in 15-20 
minutes.  
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PRO Author
s 
 
Reviews 
recommen
ding PROs  
Domains (no. 
items) 
Respo
nse 
option
s 
Scoring Target 
population 
Reca
ll 
peri
od 
Administra
tion / 
completio
n time 
 better 
QoL. 
omy ± 
adjuvant 
hormonal 
therapy. 
UCLA-
PCI 
(Univers
ity of 
Californi
a-Los 
Angeles 
Prostate 
Cancer 
Index)  
Litwin 
et al 
1995 
[31] 
Litwin 
et al 
1998 
[32] 
Rnic et al 
2013 [10] 
Morris et 
al  
2009 [8] 
Hamoen et 
al 2015 
[25] 
6 domains (20 
items): urinary 
function (5), 
sexual function 
(8), bowel 
function (4), 
urinary bother 
(1), sexual 
bother (1), 
bowel bother 
(1). 
3- to 
5-
point 
Likert 
scales. 
Item 
scores 
summed 
for the 
function 
scales 
and all 
domain 
scores 
linearly 
transfor
med to 
0-100 
scales. 
Higher 
scores = 
better 
QoL. 
 
Men 
treated for 
localised 
early stage 
prostate 
cancer 
with 
surgery, 
radiothera
py or 
watchful 
waiting. 
Last 
4 
wee
ks. 
Self-
administer
ed in 8-10 
minutes.  
 
FACT-P 
(Functio
nal 
Assessm
ent of 
Cancer 
Therapy 
– 
Prostate
)  
Esper et 
al 1997 
[33] 
Morris et 
al 2009 [8] 
Hamoen et 
al 2015 
[25] 
6 domains (39 
items). 
1 Prostate 
Cancer Subscale 
(PCS) titled 
‘additional 
concerns’ (12 
items).  
 
PCS 12 items: 
weight loss, 
appetite, pain 
bother, pain, 
pain activity 
limitation, 
comfort, 
masculine self-
perception, 
bowel 
movement, 
difficulty 
urinating, 
urinating 
frequency, 
urinating activity 
limitation, 
erection.  
 
5-
point 
Likert 
scales.  
Item 
scores 
are 
added to 
give 
summar
y score 
for each 
domain 
and a 
total 
FACT-P 
score. 
Physical 
and 
function
al 
domain 
scores 
and the 
prostate
-specific 
score 
produce 
the 
Treatme
nt 
Outcom
Men with 
localised 
or 
metastatic 
prostate 
cancer. 
Past 
7 
days
. 
Self-
administer
ed in 8-10 
minutes. 
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PRO Author
s 
 
Reviews 
recommen
ding PROs  
Domains (no. 
items) 
Respo
nse 
option
s 
Scoring Target 
population 
Reca
ll 
peri
od 
Administra
tion / 
completio
n time 
5 generic FACT-G 
domains (27 
items): physical 
well-being (7), 
social/family 
well-being (7), 
emotional well-
being (6), 
functional well-
being (7). 
e Index 
(TOI). 
Higher 
scores = 
better 
QoL. 
 
PSC 
score 
range=0-
48. 
QLQ-
PR25 
(EORTC 
Prostate
-specific 
module)  
 
 
van 
Andel 
et al 
2008 
[34] 
Morris et 
al 2009 [8] 
6 domains (25 
items): urinary 
symptoms (8), 
incontinence aid 
(1), bowel 
symptoms (4), 
hormonal 
treatment 
related 
symptoms (6), 
sexual active (2), 
sexual 
functioning (4). 
 
4-
point 
Likert 
scales.  
Item and 
scale 
scores 
transfor
med to a 
0-100 
scale. 
Higher 
scores = 
worseni
ng 
sympto
ms or 
better 
functioni
ng. 
Men with 
early or 
advanced 
localised 
prostate 
cancer. 
Past 
wee
k 
and 
last 
4 
wee
ks. 
Self-
administer
ed in 5-10 
minutes. 
PC-QoL 
(Prostat
e Cancer 
– 
Quality 
of Life)  
Giesler 
et al 
2000 
[35] 
Schmidt et 
al 2014 [9] 
Rnic et al 
2013 [10] 
 
10 domains (52 
items): Urinary 
function (5), role 
activity 
limitations (5), 
and bother (4); 
sexual function 
(7), role activity 
limitations (5), 
and bother (6); 
bowel function 
(7), role activity 
limitations (5) 
and bother (4); 
cancer worry (4). 
3- to 
7-
point 
Likert 
scales. 
Item 
scores 
summed 
and 
linearly 
transfor
med to 
0-100 
score 
range for 
each 
domain. 
Higher 
scores = 
better 
QoL. 
Men with 
clinically 
localised 
prostate 
cancer 
treated 
with 
radical 
prostatect
omy, 
radiation 
or 
watchful 
waiting. 
Past 
4 
wee
ks. 
Self-
administer
ed in 15 
minutes. 
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Table 3. Appraisal of psychometric evidence for prostate cancer-specific PROs. 
 
 STAR 
[3] 
EPIC-26 
[27,28] 
EPIC-50 
[29,30]  
UCLA-PCI 
[31,32] 
PCS 
(FACT-P) 
[33] 
EORTC 
QLQ-PR25 
[34]  
PC-
QoL 
[35] 
1. Item 
analysis/reduction 
+ ++ 0 ++ 0 0 ++ 
2. Acceptability + + ++ + + + + 
3. Reliability        
3.1 Internal consistency + +++ ++ ++ + ++ + 
3.2 Test-retest reliability 0 ++ ++ ++ 0 0 ++ 
4. Validity        
4.1 Content validity ++ + ++ ++ + ++ +++ 
4.2 Criterion-related 
validity 
       
4.2.1 Concurrent validity 0 + 0 0 0 0 0 
4.2.2 Predictive validity + 0 0 0 0 0 0 
4.3 Construct validity        
4.3.1 Within-scale 
analyses 
++ ++ ++ ++ 0 ++ ++ 
4.3.2 Analyses against 
external criteria 
       
4.3.2.1 Convergent 
validity 
0 ++ ++ ++ 0 0 ++ 
4.3.2.2 Discriminant 
validity 
0 ++ 0 + 0 + 0 
4.3.2.3 Known groups 
differences 
++ 0 +++ ++ + +++ ++ 
4.3.2.4 Hypothesis 
testing 
++ 0 0 + 0 0 0 
5. Responsiveness 0 0 0 0 + + 0 
6. Modern test theory 0 0 0 0 0 0 0 
0: not reported or no evidence in favour; +: limited evidence in favour; ++: some acceptable evidence in 
favour, but some aspects fail criteria or not 
reported; +++: acceptable evidence in favour. 
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